<DOC>
	<DOCNO>NCT02010216</DOCNO>
	<brief_summary>This open-label , single arm study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) patient rheumatoid arthritis . Patients receive RoActemra/Actemra 8 mg/kg intravenously every 4 week , alone combination standard anti-rheumatic therapy , 12 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Adult Patients With Rheumatoid Arthritis ( SVOBODA Programme )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , â‰¥ 18 year age Confirmed moderate severe rheumatoid arthritis Intolerability absence effect decrease effect rheumatoid arthritis treatment disease modify antirheumatic drug ( DMARDs ) Presence infectious disease [ tuberculosis ( Tb ) , human immunodeficiency virus ( HIV ) , virus hepatitis A/B/C ] Inadequate hematologic , renal liver function Peptic ulcer disease ( acute phase ) Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>